06.02.2024 - Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM . Seite 1
Boca Raton, Florida, Feb. 06, 2024 INmune Bio, Inc. , a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with.